Life Sciences Insight

Acutus Medical makes interim CEO permanent amid Medtronic deal, other cost-cutting moves

At the start of 2022—fresh off a year that brought in record-high revenues of $17.3 million but also a net loss of more than $117 million—Acutus Medical vowed to implement a series of cost-saving measures.

Those efforts included layoffs and a plan to simultaneously ramp up sales in certain geographic regions and narrow its product offerings, the latter of which culminated in a planned sale of Acutus’ left-heart access devices to Medtronic.

Now, several months into its cost-cutting quest, Acutus is beginning to reap the rewards of a slimmed-down business and appointed a new CEO—effective Thursday—to help navigate its next moves.